Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Vaccines Adcomm May Be Called To Review COVID-19 Vaccine Strain Changes

Executive Summary

CBER Director Peter Marks said the VRBPAC may need to opine on the immunogenicity data gathered for vaccine updates.

You may also be interested in...

US FDA v. COVID Mutants: Multi-Factorial Assessments Will Determine When Product EUAs Need To Change

Acting Commissioner Janet Woodcock offers hints as to the content of upcoming guidance on how emerging virus variants may impact vaccine and therapeutic development. US may need multivalent vaccine and multiple boosters. 

Lower Efficacy Rate Of J&J’s COVID-19 Vaccine Presents ‘Messaging Challenge’

While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.

J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It

The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts